Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by HIDETO KAWARATANI
Soluble VEGF Receptor-2 May Be a Predictive Marker of Anti-Angiogenic Therapy With Clinically Available Safe Agents
Oncology Letters
Cancer Research
Oncology
Related publications
Imatinib May Be ABL to Improve Anti-Angiogenic Therapy
Molecular and Cellular Oncology
Cancer Research
Molecular Medicine
Anti-Angiogenic Alternatives to VEGF Blockade
Clinical and Experimental Metastasis
Medicine
Cancer Research
Oncology
Serum Soluble Interleukin-2 Receptor Level Is More Sensitive Than Angiotensin-Converting Enzyme or Lysozyme for Diagnosis of Sarcoidosis and May Be a Marker of Multiple Organ Involvement
Journal of Dermatology
Dermatology
Medicine
Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-Vegf Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
Pharmaceutics
Pharmaceutical Science
Anti-Tumor Innate Immunity Activated by Intermittent Metronomic Cyclophosphamide Treatment of 9L Brain Tumor Xenografts Is Preserved by Anti-Angiogenic Drugs That Spare VEGF Receptor 2
Molecular Cancer
Cancer Research
Oncology
Molecular Medicine
Bufalin Enhances Anti-Angiogenic Effect of Sorafenib via AKT/VEGF Signaling
International Journal of Oncology
Cancer Research
Oncology
Anterior Gradient�2 as a Supervisory Marker for Tumor Vessel Normalization Induced by Anti‑angiogenic Treatment
Oncology Letters
Cancer Research
Oncology
Routine Measurement of Fibrinogen Concentration. Fibrinogen May Be Just a Marker.
BMJ
